Attys Seek $113M In Fees From Glumetza Buyers' $454M Deal
A class of direct Glumetza buyers who scored $454 million in settlements that will end several claims that drugmakers plotted to delay the generic version of the blockbuster diabetes drug asked...To view the full article, register now.
Already a subscriber? Click here to view full article